Posted by Michael Wonder on 16 Jul 2024
AusperBio receives breakthrough therapy designation for AHB-137 in chronic hepatitis B treatment
10 July 2024 - AHB-137 gains breakthrough therapy designation from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy.
AusperBio Therapeutics today announced that their investigational drug AHB-137 has received breakthrough therapy designation from the Center for Drug Evaluation of the National Medical Products Administration of China.
